Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors

Nature Clinical Practice Oncology

Volumn 6, Issue 3, 2009, Pages 143-152

  Reidy, Diane L ^a   Tang, Laura H ^a   Saltz, Leonard B ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CHLOROZOTOCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; LONG ACTING DRUG; LUTETIUM 177; MK 0646; MONOCLONAL ANTIBODY; NVP AEW 541; OCTREOTIDE; PEGINTERFERON ALPHA2B; PENTETREOTIDE IN 111; SOMATOMEDIN RECEPTOR; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90; OCTREOTIDE LU 177; OCTREOTIDE Y 90; PENTETREOTIDE;

ADVANCED CANCER; ANOREXIA; ARTIFICIAL EMBOLISM; BLOOD TOXICITY; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; HEPATIC ARTERY EMBOLIZATION; HUMAN; HYPERTENSION; INSULINOMA; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SCINTIGRAPHY; THROMBOCYTOPENIA; TUMOR REGRESSION; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG TOLERABILITY; LYMPH NODE METASTASIS; PANCREAS ISLET CELL CARCINOMA; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; EVIDENCE-BASED MEDICINE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; NEUROENDOCRINE TUMORS; PROGNOSIS; SOMATOSTATIN; STREPTOZOCIN; TREATMENT OUTCOME;

EID: 73949094846     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1326     Document Type: Review

References (79)

1. Moertel CG et al. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227-232
2. Modlin IM et al. (2006) The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab 91: 2340-2348
3. Rindi G et al. (2007) Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18: 145-149
4. Ferrone CR et al. (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: Can the WHO classification system be simplified? J Clin Oncol 25: 5609-5615
5. Van Eeden S et al. (2002) Classification of low-grade neuroendocrine tumors of midgut and unknown origin. Hum Pathol 33: 1126-1132
6. Rindi G et al. (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 451: 757-762
7. Schurr P et al. (2007) Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg 245: 273-281
8. Touzios JG et al. (2005) Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg 241: 776-783
9. Sarmiento JM et al. (2003) Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 197: 29-37
10. Chamberlain RS et al. (2000) Hepatic neuroendocrine metastases: does intervention affect outcome? J Am Coll Surg 190: 432-445
11. Ruszniewski P et al. (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71: 2624-2630
12. Eriksson BK et al. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83: 2293-2301
13. Gupta S et al. (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: The MD Anderson experience. Cancer 9: 261-267
14. Moertel C et al. (1994) The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120 302-309
15. Bloomston M et al. (2007) Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned. J Gastrointest Surg 11: 264-271
16. Lamberts SW et al. (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323: 1246-1249
17. Cwikla JB et al. (2007) Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland. Neuro Endocrinol Lett 28: 789-800
18. Dromain C et al. (2005) Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23: 70-78
19. Kumbasar B et al. (2004) Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 29: 696-702
20. Asnacios A et al. (2008) Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol 26 963-970
21. Reichlin S (1983) Somatostatin. N Engl J Med 309: 1495-1501
22. Reubi JC et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 5969-5977
23. Kvols LK et al. (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315: 663-666
24. Di Bartolomeo M et al. (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77: 402-408
25. Ruszniewski P et al. (1996) Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 39: 279-283
26. Faiss S et al. (1996) Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res 142: 193-207
27. Welin SV et al. (2004) High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151: 107-112
28. Arnold R et al. (1993) Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion 54: 72-75
29. Saltz L et al. (1993) Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72: 244-248
30. Ducreux M et al. (2000) The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95: 3276-3281
31. Panzuto F et al. (2006) Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 17: 461-466
32. Moertel CG et al. (1989) Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7: 865-888
33. Saltz L et al. (1994) A phase II trial of α-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 74: 958-961
34. Plöckinger U and Wiedenmann B (2007) Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 21: 145-162
35. Faiss S et al. (2003) Prospective, randomized multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689-2696
36. Välimäki M et al. (1991) Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67: 547-549
37. Vavra JJ et al. (1960) Streptozotocin, a new antibacterial antibiotic. Antibiot Annu 1: 230-235
38. Murray-Lyon IM et al. (1968) Treatment of multiple-hormone-producing malignant islet-cell tumor with streptozocin. Lancet 2: 895-898
39. Schein PS et al. (1974) Clinical antitumour acitivity and toxicity of streptozotocin (NSC-85998). Cancer 34: 993-1000
40. Schein P et al. (1973) Streptozocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. Arch Intern Med 132: 555-561
41. Moertel CG et al. (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189-1194
42. Moertel CG et al. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519-523
43. Cheng PN and Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86: 944-948
44. Rivera E and Ajani JA (1998) Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 21: 36-38
45. Kouvaraki MA et al. (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762-4771
46. Gonzalez MA et al. (2003) Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 89: 455-456
47. Moertel CG and Hanley JA (1979) Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2: 327-334
48. Engstrom PF et al. (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255-1259
49. Bukowski RM et al. (1987) A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60: 2891-2895
50. Sun W et al. (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23: 4897-4904
51. Ramanathan RK et al. (2001) Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 12: 1139-1143
52. Bukowski RM et al. (1994) Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73: 1505-1508
53. Kulke MH et al. (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24: 401-406
54. Varker KA et al. (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61: 661-668
55. Ekeblad S et al. (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13: 2986-2991
56. Kulke MH et al. (2007) Prediction of response to temozolomide (TMZ)-based therapy by loss of MGMT expression in patients with advanced neuroendocrine tumors (NET) [abstract #4505]. ASCO Meeting Abstracts 25: 4505
57. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 12 941-945
58. 90Y-DOTATOC. J Nucl Med 43: 610-616
59. Virgolini I et al. (2002) 111In- and 90Y-DOTA-lanreotide: Results and implications of the MAURITIUS trial. J Nucl Med 32: 148-155
60. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36: 147-156
61. 177 Lu-DOTA0,Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26: 2124-2130
62. 177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic tumors. J Clin Oncol 23: 2754-2762
63. Duran I et al. (2006) A phase II clinical and pharmacodynamic study trial of temsirolimus in advanced neuroendocrine tumors. Br J Cancer 95: 1148-1154
64. Yao JC et al. (2007) Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET) [abstract #4503]. ASCO Meeting Abstracts 25 4503
65. Terris B et al. (1998) Expression of vascular endothelial growth factor in digestive tumours. Histopathology 32: 133-138
66. Phan AT et al. (2006) Association of VEGF expression with poor prognosis among patients with low-grade neuroendocrine carcinoma [abstract #4091]. ASCO Meeting Abstracts 24: 4091
67. Yao JC et al. (2005) Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract #4007]. 2005 ASCO Meeting Abstracts 23: 4007
68. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342
69. Sandler A et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355 2542-2550
70. Miller KD et al. (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799
71. Miller K et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 2666-2676
72. Kulke MH et al. (2006) A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract #4044]. ASCO Meeting Abstracts 24: 4044
73. Kulke M et al. (2005) Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs) [abstract #718]. Eur J Cancer Suppl 3: 204
74. Nilsson O et al. (1992) Presence of IGF-1 in human midgut carcinoid tumours - an autocrine regulator of carcinoid tumour growth? Int J Cancer 51: 195-203
75. Adams TE et al. (2000) Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050-1093
76. Wang Y and Sun Y (2002) Insulin-like growth factor receptor-1 as an anti-cancer target: Blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2: 191-207
77. Pollak MN et al. (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518
78. Ouban A et al. (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803-808
79. García-Echeverría C et al. (2004) In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239